Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Comparative effect of clopidogrel plus aspirin and aspirin monotherapy on hematological parameters using propensity score matching

Authors Hayasaka M, Takahashi Y, Nishida Y, Yoshida Y, Hidaka S, Asai S

Received 18 October 2012

Accepted for publication 10 December 2012

Published 18 February 2013 Volume 2013:9 Pages 65—70

DOI https://doi.org/10.2147/VHRM.S39351

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Masatoshi Hayasaka,1 Yasuo Takahashi,2 Yayoi Nishida,2 Yoshikazu Yoshida,1 Shinji Hidaka,3 Satoshi Asai4

1Department of Pharmacy, Nihon University Itabashi Hospital, Tokyo, 2Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon University School of Medicine, Tokyo, 3Laboratory of Pharmaceutical Regulatory Science, Department of Pharmacy, School of Pharmacy, Nihon University, Chiba, 4Division of Pharmacology, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo, Japan

Background: Clopidogrel and aspirin are antiplatelet agents that are recommended to reduce the risk of recurrent stroke and other cardiovascular events. Dual antiplatelet therapy with clopidogrel and aspirin has been shown to increase the risk of hemorrhage, but the effects of the drugs on laboratory parameters have not been well studied in real-world clinical settings. Therefore, we evaluated and compared the effects of combination therapy with clopidogrel plus aspirin and aspirin monotherapy on laboratory parameters.
Methods: We used data from the Nihon University School of Medicine Clinical Data Warehouse obtained between November 2004 and May 2011 to identify cohorts of new users (n = 130) of clopidogrel (75 mg/day) plus aspirin (100 mg/day) and a propensity score matched sample of new users (n = 130) of aspirin alone (100 mg/day). We used a multivariate regression model to compare serum levels of creatinine, aspartate aminotransferase, and alanine aminotransferase, as well as hematological parameters including hemoglobin level, hematocrit, and white blood cell, red blood cell, and platelet counts up to 2 months after the start of administration of the study drugs.
Results: There were no significant differences for any characteristics and baseline laboratory parameters between users of clopidogrel plus aspirin and users of aspirin alone. Reductions in white blood cell and red blood cell counts, hemoglobin levels, and hematocrit in users of clopidogrel plus aspirin were significantly greater than those in users of aspirin alone.
Conclusion: Our findings suggest that adverse hematological effects may be greater with combination clopidogrel plus aspirin therapy than with aspirin monotherapy.

Keywords: clopidogrel, aspirin, laboratory parameter, antiplatelet therapy, propensity score matching

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study

Azar ST, Hantash HA, Jambart S, El-Zaheri MM, Rachoin R, Chalfoun A, Lahoud L, Okkeh O, Bramlage P, Brudi P, Ambegaonkar BM

Vascular Health and Risk Management 2014, 10:225-235

Published Date: 7 May 2014

Serum lipid profile and correlates in newly presenting Nigerians with arterial hypertension

Adamu UG, Okuku GA, Oladele CO, Abdullahi A, Oduh JI, Fasae AJ

Vascular Health and Risk Management 2013, 9:763-768

Published Date: 3 December 2013

Lipid profiles and inflammatory markers after periodontal treatment in children with congenital heart disease and at risk for atherosclerosis

Bresolin AC, Pronsatti MM, Pasqualotto LN, Nassar PO, Jorge AS, Silva EA, Nassar CA

Vascular Health and Risk Management 2013, 9:703-709

Published Date: 11 November 2013

Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery

Kuroda Y, Hirayama C, Hotoda H, Nishikawa Y, Nishiwaki A

Vascular Health and Risk Management 2013, 9:593-598

Published Date: 7 October 2013

Perceptions of barriers to cardiac rehabilitation use in Brazil

Ghisi GLM, Santos RZ, Aranha EE, Nunes AD, Oh P, Benetti M, Grace SL

Vascular Health and Risk Management 2013, 9:485-491

Published Date: 30 August 2013

Current status of NADPH oxidase research in cardiovascular pharmacology

Rodiño-Janeiro BK, Paradela-Dobarro B, Castiñeiras-Landeira MI, Raposeiras-Roubín S, González-Juanatey JR, Álvarez E

Vascular Health and Risk Management 2013, 9:401-428

Published Date: 25 July 2013

Short-term outcome of patients with preeclampsia

Koual M, Abbou H, Carbonnel M, Picone O, Ayoubi JM

Vascular Health and Risk Management 2013, 9:143-148

Published Date: 15 April 2013

Percutaneous mechanical thrombectomy for treatment of acute femoropopliteal bypass occlusion

Lichtenberg M, Käunicke M, Hailer B

Vascular Health and Risk Management 2012, 8:283-289

Published Date: 4 May 2012

Congenital agenesis of internal carotid artery with ipsilateral Horner presenting as focal neurological symptoms

Wassim Farhat, Rechdi Ahdab, Hassan Hosseini

Vascular Health and Risk Management 2011, 7:37-40

Published Date: 26 January 2011